Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro

George P. Amorino, Virginia M. Hamilton, Hak Choy

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

This study was designed to evaluate the combination of docetaxel (Taxotere) and carboplatin for radiopotentiation in vitro. H460 human lung carcinoma cells were treated with docetaxel (or paclitaxel) for 1 h and rinsed. After 24 h, the cells were treated with carboplatin for 1 h, irradiated, and colony forming ability was assessed. Using various doses of docetaxel with 100 μM carboplatin, the dose enhancement ratio (D.E.R.) for drugs only was 1.26. When 25 nM docetaxel was used with various doses of radiation, the radiation D.E.R. was 1.41. With all three agents combined, and after normalization for combined drug effects, the radiation D.E.R. was 1.55. Similar values were obtained using paclitaxel with these agents. Significant redistribution of cells into the radiosensitive G2/M phase was observed using a dose of paclitaxel (750 nM), which also caused radiation enhancement. However, an equally cytotoxic dose of docetaxel (25 nM) did not result in any cell cycle redistribution; this phenomenon was only observed at higher doses. This study shows that the combination of docetaxel and carboplatin enhance the effects of radiation in vitro more effectively than either drug separately. In addition, our data show that the mechanism of radiopotentiation by docetaxel probably does not involve a G2/M block in H460 cells.

Original languageEnglish (US)
Pages (from-to)343-352
Number of pages10
JournalRadiation Oncology Investigations
Volume7
Issue number6
DOIs
Publication statusPublished - 1999

    Fingerprint

Keywords

  • Carboplatin
  • Docetaxel
  • Lung cancer
  • Paclitaxel
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this